Kairos Pharma, Ltd.
KAPA
$0.785
-$0.026-3.21%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.27M | 369.00K | 159.00K | 122.00K | 1.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.45M | 383.00K | 222.00K | 287.00K | 1.09M |
| Operating Income | -1.45M | -383.00K | -222.00K | -287.00K | -1.09M |
| Income Before Tax | -980.00K | -1.05M | -253.00K | -323.00K | -1.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -980.00K | -1.05M | -253.00K | -323.00K | -1.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -980.00K | -1.05M | -253.00K | -323.00K | -1.12M |
| EBIT | -1.45M | -383.00K | -222.00K | -287.00K | -1.09M |
| EBITDA | -1.41M | -343.00K | -182.00K | -247.00K | -1.05M |
| EPS Basic | -0.07 | -0.10 | -0.02 | -0.03 | -0.11 |
| Normalized Basic EPS | -0.07 | -0.06 | -0.02 | -0.02 | -0.07 |
| EPS Diluted | -0.07 | -0.10 | -0.02 | -0.03 | -0.11 |
| Normalized Diluted EPS | -0.07 | -0.06 | -0.02 | -0.02 | -0.07 |
| Average Basic Shares Outstanding | 13.39M | 10.91M | 10.56M | 10.56M | 10.53M |
| Average Diluted Shares Outstanding | 13.39M | 10.91M | 10.56M | 10.56M | 10.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |